

Remarks/Arguments

Claims 1-7 and 10-25 are currently pending in the application. Claims 8-9 are canceled. Applicants reserve the right to pursue the canceled subject matter in a later application. No new matter is added.

Due to clerical error and problems on our end with the PDF portion of the EFT software, this response is being filed on 20 December 2007. In a telephone conversation with Examiner Kifle, it was agreed that new claims drawn to the subject matter of canceled claims 8-9 will be filed in a Continuation patent application filed concurrently herewith.

Information Disclosure Statement (IDS)

The IDS filed 24 April 2007 was not considered for failure to provide legible copies of each cited foreign document and each non-patent publication. Applicants apologize if the quality of the previous documents was not acceptable, and herewith submit a new IDS and documents for the Examiner's consideration.

§101 and §112 Rejections Overcome


Use claims 8-9 are canceled herewith. Therefore, this rejection is moot and Applicants request that it be withdrawn.

Applicants thank the Examiner for stating that claims 1-7 and 10-25 are allowed, and believe that the application is in condition for allowance. We respectfully request an action to that effect. Kindly contact the attorney listed below with any questions.

Novartis Institutes for Biomedical Research, Inc.
400 Technology Square
Cambridge, MA 02139
(617) 871-3216

Date: 20 December 2007

Respectfully submitted



Kristin Konzak
Attorney for Applicant
Reg. No. 44,848